A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

Human Psychopharmacology

Volumn 17, Issue 1, 2002, Pages 1-13

  Rosenzweig, P ^a   Canal, M ^a   Patat, A ^a   Bergougnan, L ^a   Zieleniuk, I ^a   Bianchetti, G ^a  

^a SANOFI   (France)

Author keywords

Amisulpride; Healthy volunteers; Pharmacodynamics; Pharmacokinetics; Tolerability

Indexed keywords

ALCOHOL; AMISULPRIDE; CYTOCHROME P450; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE AUTORECEPTOR; HALOPERIDOL; LORAZEPAM; PHENAZONE; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR;

ADULT; AGED; ALERTNESS; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; LIMBIC SYSTEM; LINEAR SYSTEM; MEMORY; NEGATIVE SYNDROME; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMETRY; REVIEW; SEDATION; SYMPTOMATOLOGY; TASK PERFORMANCE; URINARY EXCRETION; VOLUNTEER;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DOPAMINE; ELECTROENCEPHALOGRAPHY; HUMANS; MEMORY; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; SULPIRIDE;

EID: 0036161617     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.320     Document Type: Review

References (34)

1. Side effect profiles of new antipsychotic agents
2. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
3. Effects of neuroleptic medications on the cognition of patients with schizophrenia: A review of recent studies
4. Determination of pharmacodynamics of amisulpride by pharmaco-EEG and psychometry
5. Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI)
6. A comparison of the psychometric effects of remoxipride with those of haloperidol, thioridazine, and lorazepam in healthy volunteers
7. Positive and negative symptoms in schizophrenia
8. The effect of neuroleptics on cognitive and psychomotor function
9. Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers
10. Psychomotor impairment and cognitive disturbances induced by neuroleptics
11. Antipsychotic drug-induced dysphoria
12. Guidelines for the use of antipsychotic drugs studies in healthy volunteers
13. Pharmacokinetics of amisulpride and its enantiomers after single and repeated doses in healthy volunteers
14. The acute effects of amisulpride (50mg and 200mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers
15. Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG
16. The effects of haloperidol on visual search, eye movements and psychomotor performance
17. 2-receptor blockade and antipsychotic effects of neuroleptics. Preliminary study with positron emission tomography
18. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects
19. Paroxetine and haloperidol: Effect on psychomotor performance
20. A comparison of the CNS effects of haloperidol, chlorpromazine and sulpiride in normal volunteers
21. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose
22. The effect on neuropsychological test results of schizophrenics
23. Subjective effects of neuroleptics predict compliance
24. Effects of 50 mg of amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects
25. Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers
26. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers
27. 3 dopamine receptor antagonist activity and limbic selectivity
28. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic
29. Remoxipride versus haloperidol in healthy volunteers: Psychometric performance and subjective tolerance profiles
30. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendrocrinologic, pharmaco-EEG, and psychometric studies
31. Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trials with amisulpride and fluphenazine
32. 3 receptor antagonist with both presynaptic and limbic selectivity
33. 2 receptor
34. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients